• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells.
Abstract A targeted nanomedicine with humanized anti-EGFR scFv (NM-scFv) was developed for siRNA delivery into triple negative breast cancer (TNBC) cells. NM-scFv consisted of i) targeted nanovector (NV-scFv): nano-cargo with targeting properties; ii) siRNA: pharmacological agent and iii) cationic polymers (chitosan, poly-L-arginine): for siRNA complexation and endosomal escape. NV-scFv was based on superparamagnetic nanoparticle (SPION) labeled with DylightTM680, a PEG layer and a humanized anti-EGFR scFv. The PEG density was optimized from 236±3 to 873±4 PEGs/NV-scFv and the number of targeting ligands per NV-...
Source: European Journal of Pharmaceutics and Biopharmaceutics - October 12, 2020 Category: Drugs & Pharmacology Authors: Vinh Nguyen P, Hervé-Aubert K, David S, Lautram N, Passirani C, Chourpa I, Aubrey N, Allard-Vannier E Tags: Eur J Pharm Biopharm Source Type: research

Aptamer-Protamine-siRNA nanoparticles in targeted therapy of ErbB3 positive breast cancer cells
Publication date: Available online 9 October 2020Source: International Journal of PharmaceuticsAuthor(s): Xiangshang Xu, Li Li, Xiaolan Li, Deding Tao, Peng Zhang, Jianping Gong
Source: International Journal of Pharmaceutics - October 9, 2020 Category: Drugs & Pharmacology Source Type: research

Abnormal expression of Rap2A as a prognostic marker for human breast cancer.
CONCLUSIONS: Rap2A acted as a promotor in the development of BC. Our findings suggested that Rap2A might be a new potential therapeutic target marker for BC treatment. PMID: 33015796 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - October 7, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Strategic Design of Dicer Substrate siRNA to Mitigate the Resistance Mediated by ABCC1 in Doxorubicinresistant Breast Cancer
A. K. GATTA, R. CHANDRASHEKHAR, N. UDUPA, M. S. REDDY, S. MUTALIK AND V. R. JOSYULA*
Source: Indian Journal of Pharmaceutical Sciences - August 19, 2020 Category: Drugs & Pharmacology Source Type: research

α-Linolenic acid inhibits the migration of human triple-negative breast cancer cells by attenuating twist1 expression and suppressing twist1-mediated epithelial-mesenchymal transition.
Abstract α-Linolenic acid (ALA), an essential fatty acid, has anticancer activity in breast cancer, but the mechanism of its effects in triple-negative breast cancer (TNBC) remains unclear. We investigated the effect of ALA on Twist1, which is required to initiate epithelial-mesenchymal transition (EMT) and promotes tumor metastasis, and Twist1-mediated migration in MDA-MB231, MDA-MB468 and Hs578T cells. Twist1 protein was constitutively expressed in these TNBC cells, particularly MDA-MB-231 cells. Treatment with 100 uM ALA and Twist1 siRNA markedly decreased the Twist1 protein level and cell migration. Moreover,...
Source: Biochemical Pharmacology - July 13, 2020 Category: Drugs & Pharmacology Authors: Wang SC, Sun HL, Hsu YH, Liu SH, Lii CK, Tsai CH, Liu KL, Huang CS, Li CC Tags: Biochem Pharmacol Source Type: research

Strategic Design of Dicer Substrate siRNA to Mitigate the Resistance Mediated by ABCC1 in Doxorubicinresistant Breast Cancer
A. K. GATTA, R. CHANDRASHEKHAR, N. UDUPA, M. S. REDDY, S. MUTALIK AND V. R. JOSYULA*
Source: Indian Journal of Pharmaceutical Sciences - July 13, 2020 Category: Drugs & Pharmacology Source Type: research

The tissue transglutaminase: a potential target regulating MDR in breast cancer.
CONCLUSIONS: It is concluded that the tTG may be a potential target regulating the MDR by regulating LRP, P-gp and MRP expression as well as the expression of CD44CD24 to improve the MDR in breast cancer. PMID: 32572883 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - June 25, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Characterization of T ‐DM1‐resistant breast cancer cells
AbstractThe development of targeted therapies has drastically improved the outcome of patients with different types of cancer. T ‐DM1 (trastuzumab‐emtansine) is an antibody‐drug conjugate used for the treatment of HER2‐positive breast cancer combining the FDA approved mAb (monoclonal antibody) trastuzumab and the microtubule cytotoxic agent DM1 (emtansine). Despite clinical successes achieved by targeted therapies, a large number of patients develop resistance during treatment. To explore mechanisms of resistance to T‐DM1, the MDA‐MB‐361 HER2‐positive breast cancer cell line was exposed in vitro to T‐DM1 ...
Source: Pharmacology Research and Perspectives - June 23, 2020 Category: Drugs & Pharmacology Authors: Juliette Sauveur, Louise Conilh, Sabine Beaumel, Kamel Chettab, Lars ‐Petter Jordheim, Eva‐Laure Matera, Charles Dumontet Tags: ORIGINAL ARTICLE Source Type: research

Inhibition of CSF1R and AKT by ( ±)-kusunokinin hinders breast cancer cell proliferation.
Inhibition of CSF1R and AKT by (±)-kusunokinin hinders breast cancer cell proliferation. Biomed Pharmacother. 2020 Jun 11;129:110361 Authors: Rattanaburee T, Tipmanee V, Tedasen A, Thongpanchang T, Graidist P Abstract Kusunokinin, a lignan compound, inhibits cancer cell proliferation and induces apoptosis; however, the role of kusunokinin is not fully understood. Here, we aimed to identify a target protein of (-)-kusunokinin and determine the protein levels of its downstream molecules. We found that (-)-kusunokinin bound 5 possible target proteins, including CSF1R, MMP-12, HSP90-α, CyclinB1 and MEK1...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 10, 2020 Category: Drugs & Pharmacology Authors: Rattanaburee T, Tipmanee V, Tedasen A, Thongpanchang T, Graidist P Tags: Biomed Pharmacother Source Type: research

14,15 β‐dihydroxyklaineanone inhibits HepG2 cell proliferation and migration through p38MAPK pathway
Conclusions14,15 β‐dihydroxyklaineanone inhibited cell proliferation and migration through regulating p38 MAPK pathway in HCC cells.
Source: Journal of Pharmacy and Pharmacology - May 16, 2020 Category: Drugs & Pharmacology Authors: Xiao ‐Dong Pei, Song‐Qing He, Li‐Qun Shen, Jing‐Chen Wei, Xue‐Sheng Li, Yan‐Yan Wei, Yu‐Meng Zhang, Xin‐Yu Wang, Feng Lin, Zhi‐Long He, Li‐He Jiang Tags: Research Paper Source Type: research

Magnolin Inhibits Proliferation and Invasion of Breast Cancer MDA-MB-231 Cells by Targeting the ERK1/2 Signaling Pathway.
In conclusion, MGL inhibits proliferation and invasion of and induces apoptosis in breast cancer cells through the ERK pathway. PMID: 32378540 [PubMed - in process]
Source: Chemical and Pharmaceutical Bulletin - May 8, 2020 Category: Drugs & Pharmacology Authors: Wang J, Zhang S, Huang K, Shi L, Zhang Q Tags: Chem Pharm Bull (Tokyo) Source Type: research

Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.
Abstract Aberrant cell cycle activation is a hallmark of carcinogenesis. Recently three cell cycle targeting cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have been approved for the treatment of metastatic breast cancer. CDK4/6 inhibitors suppress proliferation through inhibition of CDK4/6-dependent retinoblastoma-1 (Rb1) phosphorylation and inactivation, a key regulatory step in G1-to-S-phase transition. Interestingly, aberrant cell cycle activation is also linked with several non-oncological diseases including acute kidney injury (AKI). AKI is a common disorder caused by toxic, inflammatory, and ischemic damag...
Source: Biochemical Pharmacology - March 26, 2020 Category: Drugs & Pharmacology Authors: Young Kim J, Jayne LA, Bai Y, Feng MJHH, Clark MA, Chung S, W Christman J, Cianciolo RE, Singh Pabla N Tags: Biochem Pharmacol Source Type: research

Chalcomoracin inhibits cell proliferation and increases sensitivity to radiotherapy in human non-small cell lung cancer cells via inducing endoplasmic reticulum stress-mediated paraptosis.
In this study, we investigated the effects of CMR against human non-small cell lung cancer cells and the underlying mechanisms. We found that CMR dose-dependently inhibited the proliferation of human lung cancer H460, A549 and PC-9 cells. Furthermore, exposure to low and median doses of CMR induced paraptosis but not apoptosis, which was presented as the formation of extensive cytoplasmic vacuolation with increased expression of endoplasmic reticulum stress markers, Bip and Chop, as well as activation of MAPK pathway in the lung cancer cells. Knockdown of Bip with siRNA not only reduced the cell-killing effect of CMR, but ...
Source: Acta Pharmacologica Sinica - February 16, 2020 Category: Drugs & Pharmacology Authors: Zhang SR, Zhang XC, Liang JF, Fang HM, Huang HX, Zhao YY, Chen XQ, Ma SL Tags: Acta Pharmacol Sin Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10